Prognostic value of CD109+ circulating endothelial cells in recurrent glioblastomas treated with bevacizumab and irinotecan.

Prognostic value of CD109+ circulating endothelial cells in recurrent glioblastomas treated with bevacizumab and irinotecan.

Item
http://www.wikidata.org/entity/Q34999120
Antiangiogenic therapy of brain tumors: the role of bevacizumab.A subpopulation of circulating endothelial cells express CD109 and is enriched in the blood of cancer patients.Parametric response maps of perfusion MRI may identify recurrent glioblastomas responsive to bevacizumab and irinotecan.Prognostic value and kinetics of circulating endothelial cells in patients with recurrent glioblastoma randomised to bevacizumab plus lomustine, bevacizumab single agent or lomustine single agent. A report from the Dutch Neuro-Oncology Group BELOB tGenome-wide association study of toxic metals and trace elements reveals novel associations.Flow cytometric analysis of circulating endothelial cells and endothelial progenitors for clinical purposes in oncology: A critical evaluation.Reduced expression of CD109 in tumor-associated endothelial cells promotes tumor progression by paracrine interleukin-8 in hepatocellular carcinomaPredictive biomarkers investigated in glioblastoma.Liquid biopsies in patients with diffuse glioma.Bevacizumab and radiotherapy for the treatment of glioblastoma: brothers in arms or unholy alliance?CD109 Mediates Cell Survival in Hepatocellular Carcinoma Cells.CD109 expression is upregulated in penile squamous cell carcinoma.Predictive and prognostic significance of circulating endothelial cells in advanced non-small cell lung cancer patients.
P2860

Prognostic value of CD109+ circulating endothelial cells in recurrent glioblastomas treated with bevacizumab and irinotecan.

Item
http://www.wikidata.org/entity/Q34999120
description
2013 nî lūn-bûn
@nan
2013 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Prognostic value of CD109+ cir ...... th bevacizumab and irinotecan.
@ast
Prognostic value of CD109+ cir ...... th bevacizumab and irinotecan.
@en
Prognostic value of CD109+ cir ...... th bevacizumab and irinotecan.
@nl
type
label
Prognostic value of CD109+ cir ...... th bevacizumab and irinotecan.
@ast
Prognostic value of CD109+ cir ...... th bevacizumab and irinotecan.
@en
Prognostic value of CD109+ cir ...... th bevacizumab and irinotecan.
@nl
prefLabel
Prognostic value of CD109+ cir ...... th bevacizumab and irinotecan.
@ast
Prognostic value of CD109+ cir ...... th bevacizumab and irinotecan.
@en
Prognostic value of CD109+ cir ...... th bevacizumab and irinotecan.
@nl
P1433
P1476
P2093
P2860
P304
P31
P356
P407
P433
P478
P50
P577
P5875
P698
P921
P932
P356
P1433
P1476
Prognostic value of CD109+ cir ...... th bevacizumab and irinotecan.
@en
P2093
P2860
P304
P31
P356
10.1371/JOURNAL.PONE.0074345
P407
P433
P478
P50
P577
P5875
P698
P921
P932